Judith Regensteiner
Concepts (505)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Intermittent Claudication | 44 | 2022 | 112 | 5.650 |
Why?
| Diabetes Mellitus, Type 2 | 54 | 2024 | 2221 | 5.260 |
Why?
| Peripheral Arterial Disease | 24 | 2022 | 398 | 3.880 |
Why?
| Exercise | 46 | 2022 | 1743 | 3.840 |
Why?
| Exercise Therapy | 31 | 2022 | 375 | 3.380 |
Why?
| Sex Characteristics | 16 | 2023 | 690 | 3.030 |
Why?
| Peripheral Vascular Diseases | 24 | 2011 | 102 | 2.660 |
Why?
| Oxygen Consumption | 33 | 2021 | 613 | 2.450 |
Why?
| Walking | 23 | 2022 | 435 | 2.290 |
Why?
| Cardiovascular Diseases | 22 | 2024 | 1859 | 2.170 |
Why?
| Sex Factors | 13 | 2022 | 1860 | 1.970 |
Why?
| Exercise Test | 37 | 2019 | 588 | 1.600 |
Why?
| Diabetes Mellitus | 16 | 2022 | 985 | 1.560 |
Why?
| Biomedical Research | 7 | 2023 | 630 | 1.500 |
Why?
| Cardiology | 6 | 2023 | 338 | 1.310 |
Why?
| Exercise Tolerance | 14 | 2024 | 245 | 1.310 |
Why?
| Quality of Life | 18 | 2019 | 2457 | 1.300 |
Why?
| American Heart Association | 10 | 2019 | 313 | 1.280 |
Why?
| Leg | 13 | 2021 | 249 | 1.160 |
Why?
| Research Personnel | 4 | 2020 | 158 | 1.110 |
Why?
| Mentoring | 3 | 2022 | 103 | 1.050 |
Why?
| Women's Health | 8 | 2023 | 277 | 1.010 |
Why?
| Humans | 172 | 2024 | 122796 | 0.960 |
Why?
| Vascular Stiffness | 3 | 2023 | 429 | 0.930 |
Why?
| Diabetic Angiopathies | 6 | 2017 | 270 | 0.930 |
Why?
| Muscle, Skeletal | 13 | 2021 | 1556 | 0.890 |
Why?
| Community Health Services | 2 | 2015 | 216 | 0.860 |
Why?
| Cardiovascular System | 5 | 2023 | 132 | 0.860 |
Why?
| Diabetic Cardiomyopathies | 3 | 2016 | 40 | 0.850 |
Why?
| Education, Medical | 3 | 2020 | 243 | 0.840 |
Why?
| Female | 95 | 2023 | 63629 | 0.790 |
Why?
| Lower Extremity | 9 | 2019 | 345 | 0.780 |
Why?
| Insulin Resistance | 12 | 2024 | 1192 | 0.780 |
Why?
| Arterial Occlusive Diseases | 7 | 2015 | 81 | 0.740 |
Why?
| Male | 90 | 2023 | 59639 | 0.740 |
Why?
| Interdisciplinary Research | 1 | 2020 | 28 | 0.730 |
Why?
| Cardiorespiratory Fitness | 2 | 2019 | 40 | 0.720 |
Why?
| Obesity | 19 | 2023 | 2786 | 0.700 |
Why?
| Sitagliptin Phosphate | 1 | 2019 | 27 | 0.700 |
Why?
| Hypoglycemic Agents | 9 | 2021 | 1055 | 0.690 |
Why?
| Endothelium, Vascular | 6 | 2021 | 923 | 0.680 |
Why?
| Aged | 54 | 2022 | 20495 | 0.680 |
Why?
| Diastole | 1 | 2019 | 147 | 0.680 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 44 | 0.670 |
Why?
| Surveys and Questionnaires | 21 | 2018 | 4882 | 0.670 |
Why?
| Middle Aged | 68 | 2019 | 28563 | 0.660 |
Why?
| Gender Identity | 1 | 2019 | 103 | 0.650 |
Why?
| Physical Fitness | 9 | 2016 | 184 | 0.650 |
Why?
| Metabolomics | 2 | 2020 | 550 | 0.630 |
Why?
| Brachial Artery | 6 | 2015 | 183 | 0.610 |
Why?
| Health Status | 4 | 2020 | 758 | 0.600 |
Why?
| Hypertension | 6 | 2022 | 1245 | 0.590 |
Why?
| Physical Exertion | 7 | 2009 | 231 | 0.580 |
Why?
| Blood Pressure | 12 | 2021 | 1713 | 0.580 |
Why?
| United States | 35 | 2023 | 13272 | 0.580 |
Why?
| Venoms | 1 | 2016 | 33 | 0.580 |
Why?
| Curriculum | 2 | 2020 | 925 | 0.580 |
Why?
| Vasodilator Agents | 3 | 2010 | 339 | 0.520 |
Why?
| Cardiac Rehabilitation | 3 | 2019 | 37 | 0.510 |
Why?
| Life Style | 9 | 2018 | 436 | 0.500 |
Why?
| National Institutes of Health (U.S.) | 4 | 2023 | 122 | 0.490 |
Why?
| Sleep | 1 | 2020 | 722 | 0.480 |
Why?
| Research Design | 4 | 2019 | 1002 | 0.470 |
Why?
| Home Care Services | 4 | 2019 | 226 | 0.460 |
Why?
| Ventricular Dysfunction, Left | 1 | 2016 | 401 | 0.440 |
Why?
| Mentors | 4 | 2022 | 170 | 0.430 |
Why?
| Physicians | 4 | 2022 | 824 | 0.430 |
Why?
| Microcirculation | 4 | 2017 | 162 | 0.430 |
Why?
| Advisory Committees | 5 | 2019 | 229 | 0.430 |
Why?
| Arteriosclerosis | 4 | 2002 | 90 | 0.430 |
Why?
| Risk Factors | 27 | 2022 | 9381 | 0.420 |
Why?
| Blood Flow Velocity | 4 | 2009 | 333 | 0.420 |
Why?
| Weight Loss | 6 | 2016 | 663 | 0.390 |
Why?
| Peptides | 1 | 2016 | 893 | 0.390 |
Why?
| Mitochondria, Muscle | 3 | 2018 | 98 | 0.380 |
Why?
| Ankle | 3 | 2008 | 72 | 0.380 |
Why?
| Diabetes Mellitus, Type 1 | 8 | 2021 | 3388 | 0.380 |
Why?
| Treatment Outcome | 23 | 2022 | 9692 | 0.380 |
Why?
| Disability Evaluation | 2 | 2011 | 291 | 0.370 |
Why?
| Longevity | 2 | 2022 | 156 | 0.370 |
Why?
| Gait | 2 | 2006 | 264 | 0.370 |
Why?
| Faculty, Medical | 4 | 2022 | 258 | 0.360 |
Why?
| Regional Blood Flow | 11 | 2020 | 427 | 0.350 |
Why?
| Tetrazoles | 3 | 2006 | 32 | 0.350 |
Why?
| Physical Endurance | 3 | 2011 | 234 | 0.340 |
Why?
| Cardiac Output, Low | 1 | 2009 | 78 | 0.340 |
Why?
| Oxygen | 4 | 2018 | 887 | 0.330 |
Why?
| Fear | 1 | 2011 | 313 | 0.330 |
Why?
| Thiazolidinediones | 3 | 2010 | 155 | 0.330 |
Why?
| Recovery of Function | 9 | 2019 | 610 | 0.330 |
Why?
| Adult | 35 | 2021 | 32385 | 0.320 |
Why?
| Research Support as Topic | 2 | 2020 | 122 | 0.320 |
Why?
| Double-Blind Method | 6 | 2019 | 1711 | 0.320 |
Why?
| Cost of Illness | 3 | 2018 | 284 | 0.320 |
Why?
| Oxidative Phosphorylation | 2 | 2019 | 160 | 0.310 |
Why?
| Glucagon-Like Peptide 1 | 2 | 2020 | 105 | 0.310 |
Why?
| Blood Glucose | 10 | 2024 | 1957 | 0.310 |
Why?
| Activities of Daily Living | 5 | 2021 | 361 | 0.310 |
Why?
| Hematologic Agents | 1 | 2006 | 2 | 0.300 |
Why?
| Perception | 1 | 2009 | 324 | 0.290 |
Why?
| Stents | 6 | 2015 | 491 | 0.290 |
Why?
| Medicare | 2 | 2022 | 767 | 0.290 |
Why?
| Feasibility Studies | 2 | 2022 | 780 | 0.280 |
Why?
| Disease Management | 4 | 2017 | 591 | 0.270 |
Why?
| Motor Activity | 5 | 2012 | 679 | 0.270 |
Why?
| Foundations | 2 | 2018 | 20 | 0.270 |
Why?
| Vascular Surgical Procedures | 5 | 2009 | 277 | 0.260 |
Why?
| Vascular Diseases | 4 | 2000 | 251 | 0.260 |
Why?
| Interdisciplinary Studies | 2 | 2017 | 26 | 0.260 |
Why?
| Echocardiography | 4 | 2018 | 591 | 0.260 |
Why?
| Societies, Medical | 3 | 2017 | 741 | 0.250 |
Why?
| Insulin | 5 | 2020 | 2180 | 0.250 |
Why?
| Vasodilation | 3 | 2015 | 462 | 0.250 |
Why?
| Respiration | 3 | 1990 | 189 | 0.240 |
Why?
| Overweight | 6 | 2023 | 516 | 0.240 |
Why?
| Heart Rate | 6 | 2015 | 756 | 0.240 |
Why?
| Pulse Wave Analysis | 3 | 2023 | 216 | 0.240 |
Why?
| Fibrinolysis | 2 | 2003 | 167 | 0.240 |
Why?
| Medroxyprogesterone | 4 | 1991 | 10 | 0.240 |
Why?
| Kinetics | 5 | 2015 | 1658 | 0.230 |
Why?
| Minority Groups | 2 | 2022 | 242 | 0.230 |
Why?
| Iliac Artery | 2 | 2014 | 46 | 0.230 |
Why?
| Muscles | 7 | 1994 | 336 | 0.230 |
Why?
| Polyhydroxyethyl Methacrylate | 1 | 2002 | 10 | 0.230 |
Why?
| Financing, Organized | 2 | 2020 | 35 | 0.220 |
Why?
| Lung Diseases | 3 | 2019 | 764 | 0.220 |
Why?
| Financial Management | 1 | 2022 | 16 | 0.220 |
Why?
| Predictive Value of Tests | 5 | 2017 | 1947 | 0.220 |
Why?
| Vitamin E | 1 | 2003 | 119 | 0.220 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2002 | 90 | 0.220 |
Why?
| Glucose Intolerance | 1 | 2024 | 140 | 0.220 |
Why?
| Endovascular Procedures | 2 | 2018 | 290 | 0.210 |
Why?
| Ascorbic Acid | 1 | 2003 | 116 | 0.210 |
Why?
| Practice Guidelines as Topic | 4 | 2019 | 1519 | 0.210 |
Why?
| Estrogens, Conjugated (USP) | 3 | 1991 | 34 | 0.210 |
Why?
| Academic Medical Centers | 3 | 2020 | 427 | 0.200 |
Why?
| Arginine | 1 | 2003 | 254 | 0.200 |
Why?
| Congresses as Topic | 2 | 2020 | 208 | 0.200 |
Why?
| Adiponectin | 2 | 2016 | 231 | 0.200 |
Why?
| Placebos | 3 | 2019 | 204 | 0.200 |
Why?
| Echocardiography, Doppler | 3 | 2016 | 105 | 0.200 |
Why?
| Organizational Innovation | 2 | 2020 | 141 | 0.200 |
Why?
| Sulfonylurea Compounds | 2 | 2019 | 43 | 0.200 |
Why?
| Interdisciplinary Communication | 2 | 2020 | 195 | 0.190 |
Why?
| Severity of Illness Index | 4 | 2009 | 2784 | 0.190 |
Why?
| Sex Distribution | 2 | 2020 | 370 | 0.190 |
Why?
| Cardiovascular Agents | 2 | 2014 | 140 | 0.190 |
Why?
| Neovascularization, Physiologic | 2 | 2012 | 192 | 0.180 |
Why?
| Patient Compliance | 4 | 2015 | 561 | 0.180 |
Why?
| Hemodynamics | 6 | 2009 | 1036 | 0.180 |
Why?
| Randomized Controlled Trials as Topic | 7 | 2006 | 1260 | 0.180 |
Why?
| Arteries | 3 | 2016 | 256 | 0.180 |
Why?
| Forearm | 2 | 2015 | 118 | 0.180 |
Why?
| Body Mass Index | 9 | 2017 | 2144 | 0.180 |
Why?
| Pediatric Obesity | 2 | 2017 | 541 | 0.170 |
Why?
| Time Factors | 10 | 2018 | 6682 | 0.170 |
Why?
| Telerehabilitation | 1 | 2019 | 25 | 0.170 |
Why?
| Adolescent | 12 | 2022 | 18948 | 0.170 |
Why?
| Body Composition | 5 | 2014 | 668 | 0.170 |
Why?
| Cross-Sectional Studies | 8 | 2014 | 4734 | 0.170 |
Why?
| Leadership | 2 | 2020 | 320 | 0.170 |
Why?
| Follow-Up Studies | 7 | 2016 | 4768 | 0.160 |
Why?
| Cause of Death | 1 | 2020 | 389 | 0.160 |
Why?
| Women's Rights | 1 | 2017 | 3 | 0.160 |
Why?
| Resistance Training | 1 | 2020 | 122 | 0.160 |
Why?
| Pentoxifylline | 3 | 2006 | 21 | 0.160 |
Why?
| Sexism | 1 | 2018 | 50 | 0.150 |
Why?
| Health Status Indicators | 4 | 2015 | 163 | 0.150 |
Why?
| Aged, 80 and over | 8 | 2012 | 6845 | 0.150 |
Why?
| Caregivers | 2 | 2022 | 723 | 0.150 |
Why?
| Program Development | 1 | 2019 | 372 | 0.150 |
Why?
| Colorado | 9 | 2017 | 4325 | 0.150 |
Why?
| Heart Diseases | 2 | 2019 | 358 | 0.150 |
Why?
| Capillaries | 3 | 2012 | 107 | 0.150 |
Why?
| Ankle Brachial Index | 2 | 2014 | 32 | 0.150 |
Why?
| Circadian Rhythm | 1 | 2020 | 414 | 0.140 |
Why?
| Death, Sudden, Cardiac | 1 | 2018 | 213 | 0.140 |
Why?
| Microvessels | 1 | 2017 | 76 | 0.140 |
Why?
| Precision Medicine | 1 | 2020 | 371 | 0.140 |
Why?
| Clinical Trials as Topic | 5 | 2019 | 985 | 0.140 |
Why?
| Case-Control Studies | 6 | 2016 | 3296 | 0.140 |
Why?
| Glucose Tolerance Test | 4 | 2024 | 370 | 0.140 |
Why?
| Health Status Disparities | 1 | 2018 | 217 | 0.140 |
Why?
| Faculty | 1 | 2017 | 133 | 0.140 |
Why?
| Reference Values | 4 | 2007 | 789 | 0.140 |
Why?
| Needs Assessment | 1 | 2018 | 345 | 0.130 |
Why?
| Ischemia | 1 | 2019 | 382 | 0.130 |
Why?
| Leptin | 1 | 2017 | 233 | 0.130 |
Why?
| Blood Vessels | 1 | 2017 | 193 | 0.130 |
Why?
| Plethysmography | 3 | 2011 | 125 | 0.130 |
Why?
| Intention to Treat Analysis | 1 | 2015 | 72 | 0.130 |
Why?
| Pilot Projects | 2 | 2015 | 1477 | 0.130 |
Why?
| Adiposity | 2 | 2017 | 523 | 0.130 |
Why?
| Cardiac Output | 1 | 2015 | 154 | 0.130 |
Why?
| Program Evaluation | 2 | 2020 | 880 | 0.130 |
Why?
| Ventricular Function | 1 | 2015 | 61 | 0.130 |
Why?
| Physical Education and Training | 1 | 1994 | 61 | 0.130 |
Why?
| Myocardium | 1 | 2020 | 982 | 0.130 |
Why?
| Arterial Pressure | 1 | 2015 | 103 | 0.120 |
Why?
| Hypoxia | 3 | 1990 | 1003 | 0.120 |
Why?
| Endothelium | 1 | 2015 | 121 | 0.120 |
Why?
| Oxidative Stress | 1 | 2021 | 1204 | 0.120 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 410 | 0.120 |
Why?
| Healthy Volunteers | 1 | 2015 | 209 | 0.120 |
Why?
| Peripheral Nervous System Diseases | 1 | 1995 | 126 | 0.120 |
Why?
| Patient Selection | 4 | 2019 | 717 | 0.120 |
Why?
| Hyperlipidemias | 3 | 2004 | 134 | 0.120 |
Why?
| Diagnostic Self Evaluation | 1 | 2013 | 27 | 0.120 |
Why?
| Angioplasty | 2 | 2009 | 41 | 0.120 |
Why?
| Aortic Diseases | 1 | 2014 | 95 | 0.120 |
Why?
| Menopause | 3 | 1991 | 270 | 0.120 |
Why?
| Health Care Costs | 2 | 2014 | 414 | 0.110 |
Why?
| Reaction Time | 1 | 2015 | 416 | 0.110 |
Why?
| Diet, Reducing | 1 | 2013 | 82 | 0.110 |
Why?
| Diabetes Complications | 3 | 2010 | 226 | 0.110 |
Why?
| Ventricular Function, Left | 1 | 2016 | 493 | 0.110 |
Why?
| Interviews as Topic | 3 | 2020 | 601 | 0.110 |
Why?
| Capacity Building | 1 | 2012 | 53 | 0.110 |
Why?
| Diabetic Nephropathies | 2 | 2014 | 292 | 0.110 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2014 | 513 | 0.110 |
Why?
| Premenopause | 2 | 2003 | 109 | 0.110 |
Why?
| Students, Medical | 1 | 2017 | 328 | 0.110 |
Why?
| Counseling | 1 | 2015 | 364 | 0.100 |
Why?
| Kidney | 2 | 2021 | 1355 | 0.100 |
Why?
| Smoking | 6 | 2010 | 1556 | 0.100 |
Why?
| Clinical Protocols | 1 | 1993 | 248 | 0.100 |
Why?
| Myocardial Revascularization | 1 | 2011 | 84 | 0.100 |
Why?
| Hemoglobins | 2 | 2017 | 293 | 0.100 |
Why?
| Health Promotion | 1 | 2017 | 707 | 0.100 |
Why?
| Research Report | 1 | 2011 | 83 | 0.100 |
Why?
| Heart Ventricles | 1 | 2016 | 741 | 0.100 |
Why?
| Benchmarking | 1 | 2012 | 184 | 0.100 |
Why?
| Linear Models | 2 | 2014 | 854 | 0.100 |
Why?
| Sickness Impact Profile | 1 | 2011 | 53 | 0.100 |
Why?
| Self Concept | 1 | 2012 | 221 | 0.100 |
Why?
| Consensus | 3 | 2019 | 554 | 0.100 |
Why?
| Hyperemia | 1 | 2011 | 43 | 0.100 |
Why?
| Fatty Acids, Nonesterified | 2 | 2009 | 173 | 0.100 |
Why?
| Comorbidity | 4 | 2021 | 1600 | 0.100 |
Why?
| Biomarkers | 5 | 2017 | 3662 | 0.100 |
Why?
| Affect | 1 | 2012 | 254 | 0.090 |
Why?
| Atherosclerosis | 2 | 2011 | 354 | 0.090 |
Why?
| Niacin | 1 | 2010 | 20 | 0.090 |
Why?
| Coronary Disease | 4 | 2004 | 372 | 0.090 |
Why?
| C-Reactive Protein | 2 | 2009 | 363 | 0.090 |
Why?
| Lovastatin | 1 | 2010 | 31 | 0.090 |
Why?
| Hypertrophy, Left Ventricular | 2 | 2009 | 112 | 0.090 |
Why?
| Body Fat Distribution | 1 | 2009 | 46 | 0.090 |
Why?
| Hospitalization | 1 | 2018 | 1914 | 0.090 |
Why?
| Gonadal Steroid Hormones | 1 | 1990 | 123 | 0.090 |
Why?
| Aorta | 1 | 2011 | 368 | 0.090 |
Why?
| Heart Function Tests | 1 | 2009 | 68 | 0.090 |
Why?
| Pulmonary Wedge Pressure | 1 | 2009 | 76 | 0.090 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2012 | 537 | 0.090 |
Why?
| Hyperinsulinism | 2 | 2010 | 109 | 0.080 |
Why?
| Thinness | 1 | 2009 | 94 | 0.080 |
Why?
| Fasting | 2 | 2005 | 266 | 0.080 |
Why?
| Psychometrics | 1 | 2012 | 672 | 0.080 |
Why?
| Perfusion | 1 | 2009 | 160 | 0.080 |
Why?
| Heart Failure | 3 | 2018 | 2114 | 0.080 |
Why?
| Age Factors | 4 | 2021 | 3114 | 0.080 |
Why?
| Analysis of Variance | 4 | 2012 | 1329 | 0.080 |
Why?
| Mitochondria | 1 | 2014 | 809 | 0.080 |
Why?
| Puberty | 1 | 2009 | 149 | 0.080 |
Why?
| Myoglobin | 1 | 2007 | 16 | 0.080 |
Why?
| Cost-Benefit Analysis | 4 | 2014 | 573 | 0.080 |
Why?
| Angina Pectoris | 1 | 2008 | 72 | 0.080 |
Why?
| Leisure Activities | 2 | 2006 | 28 | 0.080 |
Why?
| Inflammation | 3 | 2009 | 2598 | 0.080 |
Why?
| Aging | 1 | 2018 | 1694 | 0.080 |
Why?
| Young Adult | 5 | 2017 | 11094 | 0.080 |
Why?
| Awareness | 1 | 2008 | 93 | 0.070 |
Why?
| Prospective Studies | 8 | 2019 | 6704 | 0.070 |
Why?
| Prevalence | 3 | 2019 | 2442 | 0.070 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2008 | 1213 | 0.070 |
Why?
| Dyspnea | 1 | 2008 | 214 | 0.070 |
Why?
| Neoplasms | 2 | 2010 | 2235 | 0.070 |
Why?
| Glycation End Products, Advanced | 1 | 2006 | 70 | 0.070 |
Why?
| Regression Analysis | 5 | 1998 | 1018 | 0.070 |
Why?
| Chronic Disease | 2 | 2023 | 1645 | 0.070 |
Why?
| Blood Viscosity | 2 | 1995 | 19 | 0.070 |
Why?
| Multicenter Studies as Topic | 2 | 2004 | 247 | 0.070 |
Why?
| Lipids | 1 | 2009 | 614 | 0.070 |
Why?
| Metformin | 2 | 2010 | 303 | 0.070 |
Why?
| Interleukin-6 | 1 | 2009 | 702 | 0.070 |
Why?
| Hematocrit | 2 | 1995 | 94 | 0.070 |
Why?
| Glucose Clamp Technique | 1 | 2005 | 195 | 0.070 |
Why?
| Animals | 5 | 2018 | 34133 | 0.060 |
Why?
| Sulfonic Acids | 1 | 2004 | 13 | 0.060 |
Why?
| Pulmonary Circulation | 1 | 2007 | 455 | 0.060 |
Why?
| Nutrition Surveys | 1 | 2006 | 240 | 0.060 |
Why?
| Carnitine | 4 | 1996 | 64 | 0.060 |
Why?
| Population Dynamics | 1 | 1985 | 146 | 0.060 |
Why?
| Estrogens | 2 | 2010 | 325 | 0.060 |
Why?
| Cohort Studies | 3 | 2016 | 5294 | 0.060 |
Why?
| Acetates | 1 | 2004 | 100 | 0.060 |
Why?
| Incidence | 3 | 2019 | 2527 | 0.060 |
Why?
| Health Maintenance Organizations | 1 | 2004 | 110 | 0.060 |
Why?
| Dietary Carbohydrates | 1 | 2004 | 154 | 0.060 |
Why?
| Biopsy | 3 | 2012 | 1090 | 0.060 |
Why?
| Body Weight | 2 | 2006 | 958 | 0.060 |
Why?
| Intracranial Arterial Diseases | 1 | 2002 | 6 | 0.060 |
Why?
| Child | 5 | 2017 | 19561 | 0.060 |
Why?
| Genetic Vectors | 1 | 2004 | 310 | 0.060 |
Why?
| Serum Globulins | 1 | 2002 | 4 | 0.050 |
Why?
| Genetic Therapy | 1 | 2004 | 265 | 0.050 |
Why?
| Alcohol Drinking | 2 | 2010 | 668 | 0.050 |
Why?
| Prognosis | 2 | 2010 | 3563 | 0.050 |
Why?
| Dietary Fats | 1 | 2004 | 325 | 0.050 |
Why?
| Musculoskeletal Diseases | 1 | 2003 | 74 | 0.050 |
Why?
| Neovascularization, Pathologic | 1 | 2004 | 292 | 0.050 |
Why?
| Ambulatory Care | 2 | 2014 | 497 | 0.050 |
Why?
| Lung | 1 | 2015 | 3830 | 0.050 |
Why?
| Qualitative Research | 2 | 2020 | 950 | 0.050 |
Why?
| Psychomotor Performance | 1 | 2004 | 307 | 0.050 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2002 | 84 | 0.050 |
Why?
| Single-Blind Method | 2 | 2013 | 275 | 0.050 |
Why?
| Diet | 2 | 2010 | 1168 | 0.050 |
Why?
| Adipose Tissue | 1 | 2005 | 616 | 0.050 |
Why?
| Homocysteine | 1 | 2002 | 138 | 0.050 |
Why?
| Platelet Aggregation Inhibitors | 2 | 2002 | 425 | 0.050 |
Why?
| Altitude | 1 | 1985 | 425 | 0.050 |
Why?
| Fibrinogen | 1 | 2002 | 162 | 0.050 |
Why?
| Meta-Analysis as Topic | 1 | 2002 | 172 | 0.050 |
Why?
| Aorta, Thoracic | 1 | 2023 | 252 | 0.050 |
Why?
| Enzyme Inhibitors | 1 | 2004 | 836 | 0.050 |
Why?
| Cardiovascular Surgical Procedures | 1 | 2000 | 38 | 0.050 |
Why?
| Cholesterol, LDL | 2 | 2014 | 326 | 0.050 |
Why?
| Multivariate Analysis | 3 | 2014 | 1531 | 0.050 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 228 | 0.050 |
Why?
| Administration, Oral | 1 | 2003 | 786 | 0.050 |
Why?
| Medroxyprogesterone Acetate | 2 | 1990 | 30 | 0.050 |
Why?
| Myocardial Ischemia | 1 | 2002 | 267 | 0.050 |
Why?
| Pregnancy | 3 | 2020 | 5854 | 0.050 |
Why?
| Carrier Proteins | 1 | 2004 | 740 | 0.050 |
Why?
| Organization and Administration | 1 | 2019 | 11 | 0.040 |
Why?
| Tissue Plasminogen Activator | 1 | 2002 | 242 | 0.040 |
Why?
| Specialties, Surgical | 1 | 2000 | 76 | 0.040 |
Why?
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 75 | 0.040 |
Why?
| Rural Population | 2 | 1995 | 482 | 0.040 |
Why?
| Social Stigma | 1 | 2020 | 87 | 0.040 |
Why?
| Femoral Artery | 2 | 2011 | 182 | 0.040 |
Why?
| Asia | 1 | 2018 | 58 | 0.040 |
Why?
| Risk Adjustment | 1 | 2019 | 83 | 0.040 |
Why?
| Sports Medicine | 2 | 2010 | 130 | 0.040 |
Why?
| Densitometry | 1 | 1998 | 31 | 0.040 |
Why?
| Lactic Acid | 2 | 1998 | 283 | 0.040 |
Why?
| Hypercapnia | 2 | 1989 | 53 | 0.040 |
Why?
| Walking Speed | 1 | 2018 | 36 | 0.040 |
Why?
| Patient Outcome Assessment | 1 | 2019 | 130 | 0.040 |
Why?
| Depression | 1 | 2007 | 1190 | 0.040 |
Why?
| Public Health | 1 | 2023 | 480 | 0.040 |
Why?
| Cell Respiration | 1 | 2018 | 78 | 0.040 |
Why?
| Coronary Vessels | 1 | 2020 | 237 | 0.040 |
Why?
| Autonomic Nervous System | 1 | 1998 | 67 | 0.040 |
Why?
| Walk Test | 1 | 2018 | 54 | 0.040 |
Why?
| Apoptosis | 1 | 2007 | 2532 | 0.040 |
Why?
| Hand Strength | 1 | 2018 | 106 | 0.040 |
Why?
| Caloric Restriction | 1 | 2018 | 91 | 0.040 |
Why?
| Pragmatic Clinical Trials as Topic | 1 | 2017 | 47 | 0.040 |
Why?
| Neural Conduction | 2 | 1995 | 82 | 0.040 |
Why?
| Capillary Resistance | 1 | 2017 | 6 | 0.040 |
Why?
| Drug Therapy, Combination | 2 | 2010 | 988 | 0.040 |
Why?
| Weight Reduction Programs | 1 | 2018 | 95 | 0.040 |
Why?
| Secondary Prevention | 1 | 2019 | 257 | 0.040 |
Why?
| Oxyhemoglobins | 1 | 2017 | 19 | 0.040 |
Why?
| Acute Disease | 1 | 2020 | 984 | 0.040 |
Why?
| Career Choice | 1 | 2019 | 206 | 0.040 |
Why?
| Reproducibility of Results | 2 | 2013 | 2977 | 0.040 |
Why?
| Spectroscopy, Near-Infrared | 1 | 2017 | 43 | 0.040 |
Why?
| Betacoronavirus | 1 | 2020 | 265 | 0.040 |
Why?
| Family Practice | 1 | 2001 | 485 | 0.040 |
Why?
| Canada | 1 | 2018 | 355 | 0.040 |
Why?
| Bicycling | 1 | 2017 | 80 | 0.040 |
Why?
| Social Support | 1 | 2020 | 547 | 0.040 |
Why?
| Sensitivity and Specificity | 2 | 2013 | 1855 | 0.040 |
Why?
| Heart | 1 | 2020 | 649 | 0.030 |
Why?
| Forecasting | 2 | 2000 | 372 | 0.030 |
Why?
| Stroke Volume | 1 | 2018 | 553 | 0.030 |
Why?
| Vascular Resistance | 1 | 2017 | 374 | 0.030 |
Why?
| Matched-Pair Analysis | 1 | 1995 | 42 | 0.030 |
Why?
| Absorptiometry, Photon | 1 | 2016 | 230 | 0.030 |
Why?
| Energy Intake | 3 | 2006 | 453 | 0.030 |
Why?
| Retrospective Studies | 3 | 2007 | 13433 | 0.030 |
Why?
| Pneumonia, Viral | 1 | 2020 | 361 | 0.030 |
Why?
| Coronavirus Infections | 1 | 2020 | 349 | 0.030 |
Why?
| Cystatin C | 1 | 2014 | 71 | 0.030 |
Why?
| Electrophysiology | 1 | 1995 | 205 | 0.030 |
Why?
| Risk | 1 | 2017 | 890 | 0.030 |
Why?
| Vascular Patency | 1 | 2014 | 102 | 0.030 |
Why?
| Life Expectancy | 1 | 2014 | 56 | 0.030 |
Why?
| Models, Economic | 1 | 2014 | 51 | 0.030 |
Why?
| Quality-Adjusted Life Years | 1 | 2014 | 125 | 0.030 |
Why?
| Stress, Mechanical | 1 | 2016 | 440 | 0.030 |
Why?
| Patient Education as Topic | 1 | 2019 | 717 | 0.030 |
Why?
| Phosphorus | 1 | 2014 | 85 | 0.030 |
Why?
| Databases, Factual | 2 | 2011 | 1287 | 0.030 |
Why?
| Constriction, Pathologic | 1 | 2014 | 212 | 0.030 |
Why?
| Drug Costs | 1 | 2014 | 100 | 0.030 |
Why?
| Hospital Costs | 1 | 2014 | 114 | 0.030 |
Why?
| Health Behavior | 1 | 2019 | 731 | 0.030 |
Why?
| Health Education | 1 | 2016 | 332 | 0.030 |
Why?
| Carotid Stenosis | 1 | 2014 | 80 | 0.030 |
Why?
| Collateral Circulation | 2 | 2003 | 20 | 0.030 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 145 | 0.030 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2014 | 198 | 0.030 |
Why?
| Biomechanical Phenomena | 1 | 2016 | 705 | 0.030 |
Why?
| Blood Vessel Prosthesis | 1 | 2013 | 119 | 0.030 |
Why?
| Administrative Personnel | 1 | 2012 | 35 | 0.030 |
Why?
| Creatinine | 1 | 2014 | 510 | 0.030 |
Why?
| Waist Circumference | 1 | 2012 | 132 | 0.030 |
Why?
| Statistics as Topic | 1 | 2013 | 314 | 0.030 |
Why?
| Evidence-Based Medicine | 1 | 2016 | 731 | 0.030 |
Why?
| Treatment Failure | 1 | 2013 | 348 | 0.030 |
Why?
| Health Planning | 1 | 1992 | 50 | 0.030 |
Why?
| North Carolina | 1 | 2012 | 116 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 70 | 0.030 |
Why?
| Pandemics | 1 | 2020 | 1401 | 0.030 |
Why?
| Muscle Strength | 1 | 2014 | 290 | 0.030 |
Why?
| Muscle Contraction | 1 | 2014 | 415 | 0.030 |
Why?
| Behavior Therapy | 1 | 2014 | 249 | 0.030 |
Why?
| Cerebrovascular Disorders | 1 | 1992 | 91 | 0.030 |
Why?
| Estrone | 1 | 1991 | 36 | 0.030 |
Why?
| Popliteal Artery | 1 | 2011 | 63 | 0.030 |
Why?
| Radioimmunoassay | 1 | 1991 | 168 | 0.030 |
Why?
| Glomerular Filtration Rate | 1 | 2014 | 697 | 0.020 |
Why?
| C-Peptide | 1 | 1991 | 137 | 0.020 |
Why?
| Follicular Phase | 1 | 1990 | 42 | 0.020 |
Why?
| Metabolism | 1 | 1990 | 40 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2013 | 884 | 0.020 |
Why?
| Luteal Phase | 1 | 1990 | 45 | 0.020 |
Why?
| Incretins | 1 | 2010 | 15 | 0.020 |
Why?
| Receptor, IGF Type 1 | 1 | 2010 | 59 | 0.020 |
Why?
| Receptor, Insulin | 1 | 2010 | 101 | 0.020 |
Why?
| Adaptation, Physiological | 1 | 2014 | 510 | 0.020 |
Why?
| Acetylcarnitine | 1 | 1989 | 4 | 0.020 |
Why?
| Actigraphy | 1 | 2010 | 102 | 0.020 |
Why?
| Progesterone | 1 | 1991 | 243 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 839 | 0.020 |
Why?
| Health Services Research | 1 | 2012 | 380 | 0.020 |
Why?
| Attitude of Health Personnel | 1 | 2017 | 1012 | 0.020 |
Why?
| Delayed-Action Preparations | 1 | 2010 | 162 | 0.020 |
Why?
| Percutaneous Coronary Intervention | 1 | 2015 | 535 | 0.020 |
Why?
| Risk Assessment | 2 | 2009 | 3213 | 0.020 |
Why?
| Energy Metabolism | 3 | 2006 | 783 | 0.020 |
Why?
| Respiration Disorders | 1 | 1989 | 67 | 0.020 |
Why?
| Partial Pressure | 1 | 1988 | 32 | 0.020 |
Why?
| Estradiol | 1 | 1991 | 477 | 0.020 |
Why?
| Tidal Volume | 1 | 1988 | 77 | 0.020 |
Why?
| Drug Interactions | 1 | 1989 | 356 | 0.020 |
Why?
| Risk Reduction Behavior | 1 | 2009 | 205 | 0.020 |
Why?
| Fluoroquinolones | 1 | 2007 | 43 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2014 | 2599 | 0.020 |
Why?
| Pain | 1 | 1993 | 746 | 0.020 |
Why?
| Testosterone | 1 | 2010 | 353 | 0.020 |
Why?
| Caspase 3 | 1 | 2007 | 246 | 0.020 |
Why?
| Hyperglycemia | 1 | 2010 | 326 | 0.020 |
Why?
| Ankle Joint | 1 | 2008 | 170 | 0.020 |
Why?
| Models, Cardiovascular | 1 | 2007 | 183 | 0.020 |
Why?
| Receptor for Advanced Glycation End Products | 1 | 2006 | 35 | 0.020 |
Why?
| Carbon Dioxide | 1 | 1988 | 237 | 0.020 |
Why?
| Income | 1 | 2007 | 181 | 0.020 |
Why?
| Enzyme Activation | 1 | 2007 | 864 | 0.020 |
Why?
| Sterol O-Acyltransferase | 1 | 2004 | 4 | 0.020 |
Why?
| Receptors, Immunologic | 1 | 2006 | 228 | 0.020 |
Why?
| Sleep Wake Disorders | 1 | 1989 | 289 | 0.020 |
Why?
| Acetamides | 1 | 2004 | 28 | 0.020 |
Why?
| Case Management | 1 | 2004 | 65 | 0.010 |
Why?
| Gene Transfer Techniques | 1 | 2004 | 154 | 0.010 |
Why?
| Age Distribution | 1 | 2004 | 376 | 0.010 |
Why?
| Cell Adhesion Molecules | 1 | 2004 | 188 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2014 | 3264 | 0.010 |
Why?
| Calcium-Binding Proteins | 1 | 2004 | 222 | 0.010 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 373 | 0.010 |
Why?
| Cognition Disorders | 1 | 2007 | 547 | 0.010 |
Why?
| Cytokines | 1 | 2010 | 1928 | 0.010 |
Why?
| Ultrasonography, Doppler | 1 | 2001 | 105 | 0.010 |
Why?
| Artificial Limbs | 1 | 2003 | 112 | 0.010 |
Why?
| Sulfonamides | 1 | 2004 | 455 | 0.010 |
Why?
| Lactates | 2 | 1992 | 87 | 0.010 |
Why?
| Wound Healing | 1 | 2003 | 279 | 0.010 |
Why?
| Algorithms | 1 | 2008 | 1593 | 0.010 |
Why?
| World Health Organization | 1 | 2000 | 115 | 0.010 |
Why?
| Costs and Cost Analysis | 1 | 2000 | 211 | 0.010 |
Why?
| Indians, North American | 1 | 2004 | 597 | 0.010 |
Why?
| Logistic Models | 1 | 2004 | 1995 | 0.010 |
Why?
| Interpersonal Relations | 1 | 2002 | 351 | 0.010 |
Why?
| Models, Biological | 1 | 2006 | 1756 | 0.010 |
Why?
| Diabetic Neuropathies | 1 | 1998 | 100 | 0.010 |
Why?
| Patient Satisfaction | 1 | 2000 | 632 | 0.010 |
Why?
| Models, Theoretical | 1 | 2000 | 574 | 0.010 |
Why?
| Diabetic Retinopathy | 1 | 1998 | 156 | 0.010 |
Why?
| Muscle Fibers, Skeletal | 1 | 1996 | 197 | 0.010 |
Why?
| Rehabilitation | 1 | 1992 | 17 | 0.010 |
Why?
| Electromyography | 1 | 1992 | 334 | 0.010 |
Why?
| Cholesterol, HDL | 1 | 1991 | 202 | 0.010 |
Why?
| Hydroxybutyrates | 1 | 1989 | 11 | 0.010 |
Why?
| 3-Hydroxybutyric Acid | 1 | 1989 | 15 | 0.010 |
Why?
| Blood Gas Analysis | 1 | 1989 | 79 | 0.010 |
Why?
| Nervous System Diseases | 1 | 1992 | 265 | 0.010 |
Why?
| Action Potentials | 1 | 1992 | 433 | 0.010 |
Why?
| Ultrasonics | 1 | 1989 | 53 | 0.010 |
Why?
| Drug Combinations | 1 | 1989 | 292 | 0.010 |
Why?
| Sleep Apnea Syndromes | 1 | 1989 | 88 | 0.010 |
Why?
| Mice | 1 | 1989 | 15888 | 0.000 |
Why?
|
|
Regensteiner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|